PCV20 METABOLIC SYNDROME PATIENT COMPLIANCE WITH DRUG AND NON-DRUG TREATMENT

According to WHO, 30% of the world's population is anemic, 27% of anemia occurs in developing countries and 6% occurs in developed countries. The handling of anemia by the government has not been maximized so that companion therapy is needed. Objective: To see the potential of turmeric (curcuma longa) to increase hemoglobin. Methods: Search methods from Scopus, Pubmed, Elsevier, Willy and Google Scholar. Published 2010 2020. RCT research with prism technique. Analysis of 25 articles related to blood loss diseases. 2 articles on hemodialysis patients, 7 articles on thalassemia patients, 3 NAFLD patients, 4 ulcerative colitis patients, 1 prehypertension patient, 3 diabetes patients, 1 metabolic syndrome patient, 1 alanine transaminase elevated patient, 2 arthritis patients and 1 breast cancer patient. There are only 3 articles that show an increase in Hb levels, so it can be concluded that curcuma longa is not effective in increasing hemoglobin levels.

Download Full-text

Patient compliance with drug treatment ? new perspectives on an old problem

The Clinical Investigator ◽

10.1007/bf00227361 ◽

1992 ◽

Vol 70 (2) ◽

Cited By ~ 22

Author(s):

W. Kruse

Keyword(s):

Drug Treatment ◽

Patient Compliance

Download Full-text

Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia

The British Journal of Psychiatry ◽

10.1192/bjp.bp.107.041723 ◽

2008 ◽

Vol 192 (6) ◽

pp. 424-428 ◽

Cited By ~ 58

Author(s):

Olga O. Yevtushenko ◽

Stephen J. Cooper ◽

Ryan O'Neill ◽

Jennifer K. Doherty ◽

Jayne V. Woodside ◽

...

Keyword(s):

Risk Factors ◽

Metabolic Syndrome ◽

Drug Treatment ◽

Genetic Polymorphisms ◽

Genetic Risk ◽

Antipsychotic Drugs ◽

Genetic Risk Factors ◽

Metabolic Disturbances ◽

Genotype Combination ◽

Increased Risk

BackgroundObesity and metabolic syndrome are significant problems for patients taking antipsychotic drugs. Evidence is emerging of genetic risk factors.AimsTo investigate the influence of two candidate genes, smoking and drug treatment on obesity and metabolic syndrome in patients with schizophrenia.MethodPatients (n=134) were assessed for measures of obesity, other factors contributing to metabolic syndrome, and two genetic polymorphisms (5-HT2C receptor −759C/T and leptin −2548A/G).ResultsNeither genotype nor smoking was significantly associated with measures of obesity. However, both leptin genotype and smoking were significantly associated with metabolic syndrome. Significant interaction occurred between the genetic polymorphisms for effects on obesity, whereby a genotype combination increased risk. Drug treatment showed significant effects on measures of obesity and triglyceride concentrations; risperidone was associated with lower values than olanzapine or clozapine.ConclusionsThe findings suggest interacting genetic risk factors and smoking influence development of metabolic syndrome in patients on antipsychotic drugs.

Download Full-text